Partner Article
The advancement of immuno-oncology
The use of immunotherapy products to help counter cancer is one of the latest innovations in the field of oncological technology. Clinical trials of these products have shown a paradigm shift in the increase in the survival of cancer patients.
Although still in its infancy stage, the trials conducted have furnished favourable outcomes with respect to longevitiy and building of immunity of cancer patients. Therefore, further R&D of similar immuno-oncology therapies is in the pipeline.
This whitepaper on immuno-oncology http://www.researchpartnership.com/news/2015/11/free-thinking-from-promise-to-practice-immuno-oncology-in-action/ serves to provide an overview of the medical research taking place in this domain. It focusses on the finanical feasibility and technological progress of the immunotherapy products. Deeper insights regarding the practical applicability of these products in the US as well as the EU have also been explored after taking inputs from significant opinion leaders and experts in the pharmaceutical and healthcare market research field.
This was posted in Bdaily's Members' News section by Steve James .
Taking advantage of the opportunities ahead
Accountability isn’t the enemy of empathy
Act now to avoid a last-minute tax scramble
How inner-city living can transform a city by the sea
Artificial intelligence's value is the time it gives back
Why we must break the magnetic pull of London
AI scepticism is healthy - inaction isn't
What does NPPF mean for planning gain and pricing?
What new NPPF rules mean for landowners
The hidden cost squeezing Britain's economy
Teesside deserves more than cashback devolution
Construction must be built on commercial discipline